ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas

Clinical Cancer Research

Volumn 10, Issue 22, 2004, Pages 7555-7565

  De Bono, Johann Sebastian ^a,d   Tolcher, Anthony W ^a   Forero, Andre ^b   Vanhove, Gertrude F A ^c   Takimoto, Chris ^a   Bauer, Robert J ^c   Hammond, Lisa A ^a   Patnaik, Amita ^a   White, Mark L ^b   Shen, Sui ^b   Khazaeli, Muhammad B ^b   Rowinsky, Eric K ^a   LoBuglio, Albert F ^b  

^a CTRC Institute for Drug Development   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c XOMA Corporation   (United States)

^d ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

17 1A ANTIGEN; AMYLASE; CARCINOEMBRYONIC ANTIGEN; EDRECOLOMAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY ING 1; TRIACYLGLYCEROL LIPASE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADENOCARCINOMA; ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BREAST ADENOCARCINOMA; CANCER IMMUNOTHERAPY; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; DIARRHEA; DOSE TIME EFFECT RELATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FEMALE; FEVER; HEADACHE; HUMAN; HYPERAMYLASEMIA; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; LUNG ADENOCARCINOMA; MALE; NAUSEA; OVARY ADENOCARCINOMA; PANCREAS ADENOCARCINOMA; PANCREATITIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PRURITUS; RASH; SWEATING; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BODY WEIGHT; CELL ADHESION MOLECULES; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; TIME FACTORS;

EID: 9344222778     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0729     Document Type: Article

References (47)

1. Herlyn M, Steplewski Z, Herlyn D, et al. Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. Proc Natl Acad Sci USA 1979;76:1438-52.
2. Edwards DP, Grzyb KT, Dressier LG, et al. Monoclonal antibody identification and characterization of a Mr 43,000 membrane glycoprotein associated with human breast cancer. Cancer Res 1986;46:1306-17.
3. Strnad J, Hamilton AE, Beavers LS, et al. Molecular cloning and characterization of a human adenocarcinoma/epithelial cell surface antigen complementary DNA. Cancer Res 1989;49:314-7.
4. Simon B, Podolsky DK, Moldenhauer G, et al. Epithelial glycoprotein is a member of a family of epithelial cell surface antigens homologous to nidogen, a matrix adhesion protein. Proc Natl Acad Sci USA 1990;87:2755-9.
5. Szala S, Froehlich M, Scollon M, et al. Molecular cloning of cDNA for the carcinoma-associated antigen GA733-2. Proc Natl Acad Sci USA 1990;87;3542-6.
6. Balzar M, Winter MJ, de Boer CJ, et al. The biology of the 17-1A antigen (Ep-CAM). J Mol Med 1999;77:699-712.
7. Litvinov SV, Balzar M, Winter MJ, et al. Epithelial cell adhesion molecule (Ep-CAM) modulates cell-cell interactions mediated by classic cadherins. J Cell Biol 1997;139:1337-48.
8. Cirulli V, Crisa L, Beattie GM, et al. KSA antigen Ep-CAM mediates cell-cell adhesion of pancreatic epithelial cells: morphoregulatory roles in pancreatic islet development. J Cell Biol 1998;140:1519-34.
9. Schon MP, Schon M, Klein CE, et al. Properties of the carcinoma-associated antigen MH 99/KS 1/4 in normal and transformed human keratinocytes: regulation of synthesis, molecular cross-linking and ultrastructural localization. Br J Dermatol 1995;133:176-85.
10. Litvinov SV, van Driel W, van Rhijn CM, et al. Expression of Ep-CAM in cervical squamous epithelia correlates with an increased proliferation and the disappearance of markers for terminal differentiation. Am J Pathol 1996;148:865-75.
11. Schon MP, Schon M, Klein CE, et al. Carcinoma-associated 38-kD membrane glycoprotein MH 99/KS 1/4 is related to proliferation and age of transformed epithelial cell lines. J Investig Dermatol 1994;102:987-91.
12. Poczatek RB, Myers RB, Manne U, et al. Ep-Cam levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. J Urol 1999;162:1462-6.
13. Gastl G, Spizzo G, Obrist P, et al. Ep-CAM overexpression in breast cancer as a predictor of survival. Lancet 2000;356:1981-2.
14. Spizzo G, Obrist P, Ensinger C, et al. Prognostic significance of Ep-CAM AND Her-2/neu overexpression in invasive breast cancer. Int J Cancer 2002;98:883-8.
15. Mellstedt H, Fagerberg J, Frodin JE, et al. Ga733/EpCAM as a target for passive and active specific immunotherapy in patients with colorectal carcinoma. Ann N Y Acad Sci 2000;910:254-61.
16. Goodwin RA, Tuttle SE, Bucci DM, et al. Tumor-associated antigen expression of primary and metastatic colon carcinomas detected by monoclonal antibody 17-1A. Am J Clin Pathol 1987;88:462-7.
17. Momburg F, Moldenhauer G, Hammerling GJ, et al. Immunohistochemical study of the expression of a Mr 34,000 human epithelium-specific surface glycoprotein in normal and malignant tissues. Cancer Res 1987;47:2883-91.
18. McLaughlin PM, Harmsen MC, Dokter WH, et al. The epithelial glycoprotein 2 (EGP-2) promoter-driven epithelial-specific expression of EGP-2 in transgenic mice: a new model to study carcinoma-directed immunotherapy. Cancer Res 001;61:4105-11.
19. Velders MP, Litvinov SV, Warnaar SO, et al. New chimeric anti-pancarcinoma monoclonal antibody with superior cytotoxicity-mediating potency. Cancer Res 1994;54:1753-9.
20. Velders MP, van Rhijn CM, Briaire IH, et al. Immunotherapy with low and high affinity monoclonal antibodies 17-1A and 323/A3 in a nude mouse xenograft carcinoma model. Cancer Res 1995;55:4398-403.
21. LoBuglio AF, Saleh MN, Lee J, et al. Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. I. Clinical aspects. J Natl Cancer Inst (Bethesda) 1988;80:932-6.
22. Khazaeli MB, Saleh MN, Wheeler RH, et al. Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. II. Pharmacokinetics and immune response J Natl Cancer Inst (Bethesda) 1988;80:937-42.
23. Schwartzberg LS. Clinical experience with edrecolomab: a monoclonal antibody therapy for colorectal carcinoma. Crit Rev Oncol Hematol 2001;40:17-24.
24. Ragnhammar P, Fagerberg J, Frodin JE, et al. Effect of monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma-long-lasting, complete remissions can be induced. Int J Cancer 1993;53:751-8.
25. Fagerberg J, Ragnhammar P, Liljefors M, et al. Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A. Cancer Immunol Immunother 1996;42:81-7.
26. Fagerberg J, Hjelm AL, Ragnhammar P, et al. Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype-reactive T lymphocytes. Cancer Res 1995;55:1824-7.
27. Adkins JC, Spencer CM. Edrecolomab (monoclonal antibody 17-1A). Drugs 1998;56:619-26; discussion 627-8.
28. Riethmuller G, Holz E, Schlimok G, et al. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol 1998;16:1788-94.
29. Punt CJ, Nagy A, Douillard JY, et al. Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet 2002;360:671-7.
30. Fields AL, Keller AM, Schwartzberg LS, et al. Edrecolomab (17-1A antibody) in combination with 5-fluorouracil based chemotherapy in the adjuvant treatment of stage III colon cancer: results of a randomised North American phase III study [abstract]. Proc Am Soc Clin Oncol 2002;21:128.
31. Animons WS, Bauer RJ, Horwitz AH, et al. In vitro and in vivo pharmacology and pharmacokinetics of a Human Engineered monoclonal antibody to epithelial cell adhesion molecule. Neoplasia 2003;5:146-54.
32. Studnicka GM, Scares S, Better M, et al. Human-engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementarity-modulating residues. Protein Eng 1994;7:805-14.
33. Bauer R, Ruan H, Chen Z, et al. Pharmacokinetics of Human-Engineered ING-1(heMAb) in rats and cynomolgus monkeys [abstract]. Proc Am Assoc Cancer Res 2002;43:428.
34. Meredith RF, LoBuglio AF, Plott WE, et al. Pharmacokinetics, immune response, and biodistribution of iodine-131-labeled chimeric mouse/human IgG1,k 17-1A monoclonal antibody. J Nucl Med 1991;32:1162-8.
35. Eary JF, Appelbaum FL, Durack L, et al. Preliminary validation of the opposing view method for quantitative gamma camera imaging. Med Phys 1989;16:382-7.
36. Thomas SR, Maxon HR, Kereiakes JG. In vivo quantitation of lesion radioactivity using external counting methods. Med Phys 1976;03:253-5.
37. Shen S, DeNardo GL, DeNardo SJ. Quantitative bremsstrahlung imaging of yttrium-90 using a Wiener filter. Med Phys 1994;21:1409-17.
38. DeNardo GL, DeNardo SJ, Macey DJ, et al. Quantitative pharmacokinetics of radiolabeled monoclonal antibodies for imaging and therapy in patients. In: Srivastava SC, ed. Radiolabeled monoclonal antibodies for imaging and therapy. New York: Plenum Press; 1988. p. 293-310.
39. Kievit E, Pinedo HM, Schluper HM, et al. Comparison of monoclonal antibodies 17-1A and 323/A3: the influence of the affinity on tumour uptake and efficacy of radioimmunotherapy in human ovarian cancer xenografts. Br J Cancer 1996;73:457-64.
40. Wiseman G, Scott A, Lee F, et al. Chimeric G250 (cG250) monoclonal antibody phase I dose escalation trial in patients with advanced renal cell carcinoma (RCC) [abstract]. Proc Am Soc Clin Oncol 2001;20:257.
41. Posey J, Ng T, Yang B, et al. A phase I trial of an anti-KDR (VEGFR) chimeric antibody in patients with liver metastases in colorectal cancer (CRC) [abstract]. Proc Am Soc Clin Oncol 2002;21:17.
42. Takiyama Y, Tempero MA, Takasaki H, et al. Reactivity of C017-1A and B72.3 in benign and malignant pancreatic diseases. Hum Pathol 1989;20:832-8.
43. Saleh M, Posey J, Khazaeli M, et al. Phase I trial testing multiple doses of humanized monoclonal antibody (MAb) 3622W94 [abstract]. Proc Am Soc Clin Oncol 1998;17:436.
44. LoBuglio A, Saleh M, Braddock J, et al. A phase I trial of the humanized anti-EGP40 monoclonal antibody 3622W94 [abstract]. Proc Am Soc Clin Oncol 1997;16:436.
45. Waldmann T, Strober W, Blaese R. Variations in the metabolism of immunoglobulins measured by turnover rates. Washington DC: National Academy of Sciences; 1970. p. 33-51.
46. Bauer RJ, Dedrick RL, White ML, et al. Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hul 124 in human subjects with psoriasis. J Pharmacokinet Biopharm 1999;27:397-420.
47. Boyle CC, Paine AJ, Mather SJ. The mechanism of hepatic uptake of a radiolabelled monoclonal antibody. Int J Cancer 1992;50:912-7.